4943-86-6

Basic information

• Product Name: 2-AMINO-N-(4-CHLORO-PHENYL)-BENZAMIDE
• Synonyms: Benzanilide,2-amino-4'-chloro- (7CI,8CI);2-Amino-4'-chlorobenzanilide;2-Amino-N-(4-chlorophenyl)benzamide;4-Chloroanthranilanilide
• CAS NO: 4943-86-6
• Molecular Formula: C₁₃H₁₁ClN₂O
• Molecular Weight: 246.7
• Mol File: 4943-86-6.mol
• Article Data: 41

Chemical Properties

• Melting Point: 148-149 °C
• Boiling Point: 337.2 °C at 760 mmHg
• Flash Point: 157.7 °C
• Appearance: /
• Density: 1.351 g/cm³
• Vapor Pressure: 0.000107mmHg at 25°C
• Refractive Index: 1.692
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 12.37±0.70(Predicted)
• CAS DataBase Reference: 2-AMINO-N-(4-CHLORO-PHENYL)-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-N-(4-CHLORO-PHENYL)-BENZAMIDE(4943-86-6)
• EPA Substance Registry System: 2-AMINO-N-(4-CHLORO-PHENYL)-BENZAMIDE(4943-86-6)

Safety Data

• Hazardous Substances Data: 4943-86-6(Hazardous Substances Data)

Usage

General Description

2-Amino-N-(4-chloro-phenyl)-benzamide is a chemical compound that belongs to the class of benzamides. It is an organic compound with a molecular formula C13H11ClN2O. This chemical is often used in biological and pharmaceutical research as it has shown potential as a therapeutic agent. Its structure contains an amino group and a chlorine-substituted phenyl ring, which give it specific properties that make it useful in various applications. It has also been studied for its potential in the treatment of certain medical conditions, and its structural features make it an important compound in the field of medicinal chemistry.

InChI:InChI=1/C13H11ClN2O/c14-9-5-7-10(8-6-9)16-13(17)11-3-1-2-4-12(11)15/h1-8H,15H2,(H,16,17)

Upstream product

• 118-48-9 isatoic anhydride 
• 106-47-8 4-chloro-aniline 
• 41562-57-6 2-nitro-N-(4-chlorophenyl)benzamide 
• 118-92-3 anthranilic acid 
• 123767-94-2 anthraniloyl chloride ; hydrochloride 
• 271-58-9 anthranil 
• 5344-90-1 2-Aminobenzyl alcohol 
• 91-56-5 indole-2,3-dione 
• 552-16-9 ortho-nitrobenzoic acid 
• 610-14-0 2-nitrobenzyl chloride 

Downstream Products

• 20887-03-0 N-(2-aminobenzyl)-4-chloroaniline 
• 16082-00-1 o-Amido-thiobenz-N-(p-chlor-phenyl)-amid 
• 1788-93-8 3-(4-chlorophenyl)-2-methyl-3H-quinazolin-4-one 
• 24122-31-4 3-(4-chlorophenyl)quinazolin-4(3H)-one 
• 19857-35-3 2-phenyl-3-(4-chlorophenyl)-quinazoline-4(3H)-one 
• 219490-14-9 2-[(4-tert-Butylbenzoyl)amino]-N-(4-chlorophenyl)benzamide 
• 63384-39-4 3-(4-chlorophenyl)-2-phenyl-2,3-dihydroquinazolin-4(1H)-one 
• 1028-40-6 3-(4-chlorophenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one 
• 1374321-48-8 N-(4-chlorophenyl)-2-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-amine 
• 1374321-44-4 N-(4-chlorophenyl)-2-(4-fluorophenyl)-1,2-dihydroquinazolin-4-amine 
• 1374321-41-1 N-(4-chlorophenyl)-2-phenyl-1,2-dihydroquinazolin-4-amine 
• 1262424-48-5 N-(4-chlorophenyl)-2-(p-tolyl)-1,2-dihydroquinazolin-4-amine 
• 269390-69-4 VEGF Receptor Tyrosine Kinase Inhibitor II 
• 143424-17-3 N-2,4-dimethoxybenzylideneanthranil-4-chloroanilide 

Relevant articles and documents

Palladium(0)-catalysed regioselective cyclisations of 2-amino(tosyl) benzamides/sulphonamides: The stereoselective synthesis of 3-ylidene-[1,4]benzodiazepin-5-ones/benzo[f][1,2,5]thiadiazepine-1,1-dioxides

The Pd(0) catalysed cyclisation reactions betweentert-butyl propargyl carbonates and 2-aminotosyl benzamides or sulphonamides deliver 1,4-benzodiazepin-5-ones or sultam derivatives, key components of many biologically active compounds. But 2-amino benzamides/sulphonamides require propargyl carbonates substituted at acetylenic carbon to undergo the reaction resulting in the stereoselective formation of the said products.

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Design, synthesis, in vitro and in silico biological assays of new quinazolinone-2-thio-metronidazole derivatives

A new series of quinazolinone-2-thio-metronidazole derivatives 9a-o was designed, synthesized and assayed for their activities against metabolic enzymes human carbonic anhydrase I and II (hCAs I and II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glucosidase. The results indicated that all the synthesized compounds exhibited excellent inhibitory activities against mentioned enzymes as compared with standard inhibitors. Representatively, the most potent compound against CA enzymes, 4-fluorophenyl derivative 9i, was 4 and 7-times more potent than standard inhibitor acetazolamide against hCA I and II, respectively; 4-fluorobenzyl derivative 9m as the most potent compound against cholinesterase enzymes, was around 11 and 21-times more potent than standard inhibitor tacrine against AChE and BChE, respectively; the most active α-glucosidase inhibitor 9h with 4-methoxyphenyl moiety was 5-times more active that acarbose as standard inhibitor. Furthermore, in order to study interaction modes of the most potent compounds in the active site of their related enzymes, molecular modeling was performed. Druglikeness, ADME, and toxicity profile of the compounds 9i, 9m, and 9h were also predicted.